Navigation Links
InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
Date:7/23/2012

BRISBANE, Calif., July 23, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2012.  InterMune also reported a successful and early conclusion of negotiations for the reimbursement price of Esbriet® (pirfenidone) in Germany.  Effective September 15, 2012, the net ex-factory Esbriet price in Germany will be 26,999 €, or approximately $33,000 per patient per year, representing an approximate 10% discount from the current price.

InterMune reported Esbriet net revenue in the second quarter of 2012 of $5.5 million, an increase of 13 percent from $4.9 million in the first quarter of 2012.  The initial commercial launch of Esbriet was in Germany in September 2011.  Esbriet is InterMune's product marketed in Europe for adults with mild-to-moderate idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease of the lungs.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are very pleased to have negotiated with the German authorities a strong price for Esbriet, the first orphan drug that has undergone pricing and reimbursement review under Germany's new AMNOG law.  The conclusion of this favorable pricing and reimbursement negotiation brings welcome clarity and confidence to German physicians regarding the reimbursement status of Esbriet. 

"Esbriet continues to be one of the most successful orphan product launches in Germany, achieving revenues and new patient starts consistent with the best of these launches after nine months of marketing," Mr. Welch continued.  "Esbriet is on track to become the drug of choice among pulmonologists in Germany who care for IPF patients, and has begun displacing so-called triple combination therapy.  We believe that in addition to t
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. InterMune to Divest Actimmune® (Interferon Gamma-1b)
2. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
3. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
4. Herborium Group Reports Record 6 Month Revenues
5. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
6. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
7. HealthWarehouse.com Reports 82% Year-Over-Year Revenue Growth
8. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
9. China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012
10. GenVec Reports Inducement Award
11. China Kanghui Holdings Reports First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
(Date:8/19/2014)... , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today ... Annual Meeting of the American Academy of ... Care Surgery in Philadelphia, Pennsylvania ... The presentation will report results from a recently ...
Breaking Medicine Technology:AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... NEW YORK, Oct. 31 A recent outbreak ... to,as "the superbug," should cause organizations and facilities ... The superbug is resistant to common antibiotics. ... abscesses, boils and other pus-filled,lesions. Superbug infections prior ...
... Oct. 31 United,Therapeutics Corporation (Nasdaq: UTHR ... today that they will release the results of ... formulation of treprostinil,in pulmonary arterial hypertension (PAH) before ... Therapeutics will expand its previously scheduled conference,call on ...
Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
(Date:8/20/2014)... IQ Formulations , a top national health ... Inc. 500 , distinguishing it as one of the fastest ... only made the list, but was ranked in the top ... three years. It also ranked ninth among all health companies, ... second fastest growing company in the Miami metro area. ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... Awards. PM360, a leading health-marketing industry trade magazine, will ... 2009, the Trailblazer Awards are given to outstanding companies, ... has to offer. , “We are proud to ... our call to entries with double the number of ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... world’s largest nutrition school, is proud to announce ... Integral Studies (CIIS), a cutting-edge university offering ... Nutrition’s Health Coach Training Program are now eligible ... of Arts in Integrative Health Studies. , “I’m ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... cohort studies on the association of alcohol consumption with colorectal ... 2 from Australia, 13 from Western Europe, and 24 from ... least at higher levels of consumption, is associated with an ... was no increase in the risk for consumers reporting an ...
... , TUESDAY, Sept. 13 (HealthDay News) --The lifestyle changes ... disease may also improve sexual function in men with ... from the Mayo Clinic in Rochester, Minn., analyzed six ... determine how lifestyle changes and drugs used to treat ...
... for an effective vaccine and treatment against the potentially fatal ... the discovery of two ,Achilles, heels, within the virus. ... South Wales (UNSW) studied individuals at high risk of HCV ... the onset of infection. Using a new technique ...
... Canadian researchers has found the first evidence that lifelong ... While hearing studies have already shown that trained musicians ... is the first study to examine hearing abilities in ... 18 to 91 years of age. The study ...
... HealthDay Reporter , MONDAY, Sept. 12 (HealthDay News) -- ... become fathers, perhaps because they don,t need to compete with ... with their children. The findings don,t prove that fatherhood ... hormonal systems in men may detect that they,ve become fathers ...
... MONDAY, Sept. 12 (HealthDay News) -- Implantable electronic devices ... heart conditions and save lives, but these benefits may ... complications, a new study suggests. Researchers from the ... that people who develop an infection related to a ...
Cached Medicine News:Health News:Relation of alcohol consumption to colorectal cancer 2Health News:Breakthrough opens new avenues for hep C vaccine 2Health News:Science finding is music to the ears 2Health News:Testosterone Levels Seem to Fall With Fatherhood 2Health News:Testosterone Levels Seem to Fall With Fatherhood 3Health News:Heart Devices Like Pacemakers Linked to Infections 2
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Medicine Products: